WO2014087323A3 - Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques - Google Patents
Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques Download PDFInfo
- Publication number
- WO2014087323A3 WO2014087323A3 PCT/IB2013/060581 IB2013060581W WO2014087323A3 WO 2014087323 A3 WO2014087323 A3 WO 2014087323A3 IB 2013060581 W IB2013060581 W IB 2013060581W WO 2014087323 A3 WO2014087323 A3 WO 2014087323A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compounds
- treatment
- autoimmune
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/60—Maleic acid esters; Fumaric acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne des composés de formule I, de formule II, de formule III et de formule IV ou leurs sels pharmaceutiquement acceptables, ainsi que des polymorphes, des solvates, des énantiomères, des stéréo-isomères et des hydrates de ceux-ci. Les compositions pharmaceutiques comprennent une quantité efficace de composés de formule I, de formule II, de formule III ou de formule IV et des procédés pour le traitement de maladies auto-immunes et métaboliques chroniques peuvent être formulées pour une administration orale, buccale, rectale, topique, transdermique, transmucosale, intraveineuse, parentérale, un sirop ou une injection. De telles compositions peuvent être utilisées pour le traitement de maladies neurodégénératives, de maladies métaboliques, de maladies rénales chroniques et de maladies auto-immunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5091/CHE/2012 | 2012-12-06 | ||
IN5091CH2012 | 2012-12-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014087323A2 WO2014087323A2 (fr) | 2014-06-12 |
WO2014087323A3 true WO2014087323A3 (fr) | 2014-12-24 |
Family
ID=50884097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/060581 WO2014087323A2 (fr) | 2012-12-06 | 2013-12-03 | Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014087323A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207403A (zh) * | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
SG11201704282UA (en) * | 2014-12-01 | 2017-06-29 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
CN111440105B (zh) * | 2020-04-01 | 2022-05-17 | 南通华山药业有限公司 | 阿法骨化醇氨基甲酸酯衍生物及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131995A1 (fr) * | 1983-07-19 | 1985-01-23 | Maggioni-Winthrop S.P.A. | Composés à activité hypolipémique |
US5120738A (en) * | 1989-10-06 | 1992-06-09 | Fujirebio Inc. | Pantothenic acid derivatives |
US20010002404A1 (en) * | 1996-05-22 | 2001-05-31 | Webb Nigel L. | Fatty acid-pharmaceutical agent conjugates |
WO2011106688A1 (fr) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Conjugués de bis-acide gras et leurs utilisations |
WO2012161798A1 (fr) * | 2011-02-25 | 2012-11-29 | Catabasis Pharmaceuticals, Inc. | Conjugués d'acide gras et d'acide gamma-aminobutyrique (gaba) et leurs applications |
WO2014068463A2 (fr) * | 2012-11-03 | 2014-05-08 | Mahesh Kandula | Compositions et procédés de traitement d'une inflammation et de troubles métaboliques |
-
2013
- 2013-12-03 WO PCT/IB2013/060581 patent/WO2014087323A2/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131995A1 (fr) * | 1983-07-19 | 1985-01-23 | Maggioni-Winthrop S.P.A. | Composés à activité hypolipémique |
US5120738A (en) * | 1989-10-06 | 1992-06-09 | Fujirebio Inc. | Pantothenic acid derivatives |
US20010002404A1 (en) * | 1996-05-22 | 2001-05-31 | Webb Nigel L. | Fatty acid-pharmaceutical agent conjugates |
WO2011106688A1 (fr) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Conjugués de bis-acide gras et leurs utilisations |
WO2012161798A1 (fr) * | 2011-02-25 | 2012-11-29 | Catabasis Pharmaceuticals, Inc. | Conjugués d'acide gras et d'acide gamma-aminobutyrique (gaba) et leurs applications |
WO2014068463A2 (fr) * | 2012-11-03 | 2014-05-08 | Mahesh Kandula | Compositions et procédés de traitement d'une inflammation et de troubles métaboliques |
Also Published As
Publication number | Publication date |
---|---|
WO2014087323A2 (fr) | 2014-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ608116A (en) | Triazine-oxadiazoles | |
WO2013175376A3 (fr) | Compositions et méthodes de traitement de la douleur locale | |
TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
WO2013175377A3 (fr) | Compositions et méthodes pour le traitement de la mucosite | |
WO2014174425A3 (fr) | Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques | |
WO2014068463A3 (fr) | Compositions et procédés de traitement d'une inflammation et de troubles métaboliques | |
WO2016046680A3 (fr) | Compositions et procédés de traitement de maladies métaboliques hépatiques | |
WO2014141057A3 (fr) | Compositions et méthodes de traitement du cancer | |
MX2013013950A (es) | Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina. | |
WO2014087307A3 (fr) | Compositions et procédés pour le traitement du syndrome métabolique et du diabète | |
WO2013175359A3 (fr) | Compositions et méthodes pour le traitement de la sclérose en plaques | |
WO2014091384A3 (fr) | Compositions et méthodes pour le traitement de la mucosite | |
WO2014087323A3 (fr) | Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques | |
WO2014080307A3 (fr) | Compositions et procédés pour le traitement du diabète et du pré-diabète | |
WO2014006529A3 (fr) | Compositions et méthodes de traitement de la douleur modérée à aiguë | |
WO2014097137A3 (fr) | Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques | |
WO2014106804A3 (fr) | Compositions et procédés de traitement du syndrome métabolique et du diabète | |
WO2014195850A3 (fr) | Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques | |
WO2013167989A3 (fr) | Compositions et méthodes de traitement de troubles neurologiques | |
WO2014068506A3 (fr) | Compositions et procédés pour le traitement de maladies autoimmunes | |
WO2013175344A3 (fr) | Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde | |
WO2015028976A3 (fr) | Composés et méthodes de traitement de maladies inflammatoires | |
WO2014068461A3 (fr) | Compositions et méthodes de traitement d'une inflammation aiguë | |
WO2014037834A3 (fr) | Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques | |
WO2014122621A3 (fr) | Compositions et procédés pour le traitement d'états métaboliques et de maladies neuromusculaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13860394 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13860394 Country of ref document: EP Kind code of ref document: A2 |